CTOs on the Move

Rafael Pharmaceuticals

www.rafaelpharma.com

 
We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

SOLESIS

Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.

Anji Pharmaceuticals

Anji Pharma is a global pharmaceutical company focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

CERTUS PHARMACEUTICALS

CERTUS PHARMACEUTICALS is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Twin Boro Physical Therapy

With 42 locations in 10 New Jersey counties, Twin Boro Physical Therapy could not be more convenient! Our skilled physical therapists match the proper techniques with each patients ailment and body.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.